1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. News
  7. Summary
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

I-Mab Doses First Phase 2 Clinical Trial of Efineptakin Alfa, Keyrtruda Combination in Advanced Solid Tumors

01/12/2022 | 09:20am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
I-MAB -11.97% 10.74 Delayed Quote.-77.34%
MERCK & CO., INC. 1.59% 93.55 Delayed Quote.22.06%
All news about I-MAB
05/19I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiate..
PR
05/19I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiate..
CI
04/28I MAB : Provides Business and Corporate Updates and Reports Financial Results for the Year..
PU
04/28I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip..
PR
04/28I-Mab Announces Executive Appointments
CI
04/28I MAB : Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip ..
PU
04/28I MAB : Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip ..
PU
04/20I-Mab Shares Jump After Media Report Says It's Considering a Sale
MT
04/20I-Mab Reportedly Exploring Possible Sale Amid Takeover Interest
CI
04/01I-Mab Key Stockholders Voluntarily Enter 180-Day Share Lock-Up -- Stock Jumps
MT
More news
Analyst Recommendations on I-MAB
More recommendations
Financials (USD)
Sales 2022 111 M - -
Net income 2022 -217 M - -
Net cash 2022 226 M - -
P/E ratio 2022 -5,20x
Yield 2022 -
Capitalization 887 M 887 M -
EV / Sales 2022 5,95x
EV / Sales 2023 5,62x
Nbr of Employees 378
Free-Float 98,8%
Chart I-MAB
Duration : Period :
I-Mab Technical Analysis Chart | IMAB | US44975P1030 | MarketScreener
Technical analysis trends I-MAB
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 10,74 $
Average target price 82,55 $
Spread / Average Target 669%
EPS Revisions
Managers and Directors
Jing Wu Zang Chairman & Chief Executive Officer
Zheru Zhang President & Director
Xiu Xuan Zhu President & Director
John Long Chief Financial Officer & Director
John Hayslip Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
I-MAB-77.34%887
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707